<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104933</url>
  </required_header>
  <id_info>
    <org_study_id>0530-N-16</org_study_id>
    <nct_id>NCT03104933</nct_id>
  </id_info>
  <brief_title>Proadrenomedullin and Copeptin in Patients With Septic Shock</brief_title>
  <acronym>proADM</acronym>
  <official_title>Proadrenomedullin and Copeptin as Predictors of Vasopressor Requirements and Volume Resuscitation in Patients With Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Network for Research in Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Network for Research in Infectious Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the usefulness of pro-adrenomedullin (precursor of a vasodilatory
      peptide involved in septic shock pathogenesis) and copeptin (a stable peptide of the arginine
      vasopressin precursor) to predict, at the moment of septic shock diagnosis or their changes
      at 6 hours, the vasopressor requirements (measured by inotropic index and vasopressor
      dependency ratio) and volume requirement for resuscitation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of proADM and Copeptin as predictors of vasopressor requirements (measured by index inotropic and vasopressor dependency ratio) and fluid requirement</measure>
    <time_frame>the first 72 hours.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of proADM and Copeptin as predictors of organ dysfunction</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of proADM and Copeptin as predictor of 28-day mortality rate</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of proADM and Copeptin as predictors of lactate clearance</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Patients with septic shock</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients with septic shock
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18 years

          -  Diagnosis of septic shock

          -  Obtaining written informed consent.

        Exclusion Criteria:

          -  Initial dose of norepinephrine at ICU admission ≥ 0.6 mg / kg / min.

          -  Acute myocardial infarction in the previous month.

          -  History of pituitary surgery.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Garnacho-Montero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>José Garnacho-Montero, MD</last_name>
    <phone>+349552000</phone>
    <email>jose.garnacho.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>José Garnacho-Montero</name>
      <address>
        <city>Seville</city>
        <zip>41108</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Garnacho-Montero, MD</last_name>
      <phone>+349552000</phone>
      <email>jose.garnacho.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spanish Network for Research in Infectious Diseases</investigator_affiliation>
    <investigator_full_name>José Garnacho Montero</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Proadrenomedullin</keyword>
  <keyword>Copeptin</keyword>
  <keyword>Vasopressors</keyword>
  <keyword>Septic Shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Diabetes Insipidus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arginine Vasopressin</mesh_term>
    <mesh_term>Adrenomedullin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

